Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Vicore Pharma Holding AB ( (SE:VICO) ) is now available.
Vicore Pharma Holding AB has successfully raised approximately USD 48 million through a directed share issue, which was oversubscribed by institutional healthcare investors. The funds will primarily be used to expand the Phase 2b ASPIRE trial of buloxibutid in idiopathic pulmonary fibrosis, increasing the sample size to enhance the trial’s statistical power and potential for success. This strategic move aims to position Vicore as a leader in developing disease-modifying treatments for IPF, with the trial’s completion expected in the first half of 2026.
More about Vicore Pharma Holding AB
Vicore Pharma Holding AB is a pharmaceutical company focused on developing treatments for rare lung diseases. The company is primarily engaged in the development of buloxibutid, a first-in-class oral small molecule AT2 receptor agonist, which is being investigated for its potential to modify disease progression in idiopathic pulmonary fibrosis (IPF). Vicore is committed to addressing unmet medical needs in this area and has received Orphan Drug and Fast Track designation from the FDA for buloxibutid.
Average Trading Volume: 671,384
Technical Sentiment Signal: Sell
Current Market Cap: SEK2.38B
See more insights into VICO stock on TipRanks’ Stock Analysis page.